Piper Jaffray Starts Genocea Biosciences (GNCA) at Overweight

Piper Jaffray initiates coverage on Genocea Biosciences (NASDAQ: GNCA) with a Overweight rating and a price target of $14.00.

Analyst Edward Tenthoff commented, "Genocea is a next generation vaccine company developing candidates that elicit a T-cell response versus B-cell immunity of traditional vaccines. Genocea will report Phase II data from its two lead vaccines this year. GEN-003 is a therapeutic vaccine for genital herpes targeting HSV-2 with top-line data from a 310-patient Phase II trial in late 2Q:15. GEN-004 is a prophylactic vaccine for pneumococcus with data from a 90-patient Phase II "challenge" study in 4Q:15. GEN-004 could be a universal vaccine that improves on Pfizer's blockbuster Prevnar13. We expect clinical data this year to drive value and position Genocea as a potential acquisition target by a larger vaccine player."

For an analyst ratings summary and ratings history on Genocea Biosciences click here. For more ratings news on Genocea Biosciences click here.

Shares of Genocea Biosciences closed at $9.76 yesterday.

You May Also Be Interested In

• Evercore ISI Starts NVIDIA (NVDA) at Outperform
• Evercore ISI Starts Astera Labs (ALAB) at Outperform
• Citi Downgrades Endeavor Group Holdings Inc (EDR) to Neutral